WCLC26 Highlights
🔹EGFR: Adjuvant #osimertinib → 74% 8-year OS in stage II-IIIA disease
🔹ROS1+: #Zidesamtinib → 94% response rate with strong intracranial activity
🔹HER2: T-DXd → improved PFS, but pulmonary safety remains a concern
🔹EGFR exon 20ins: #Amivantamab + chemotherapy → 34.3-month median OS

Zidesamtinib Shows Promising Results in ROS1-Positive NSCLC Patients #South_Korea #Seoul #NSCLC #zidesamtinib #ROS1-positive